catocencoris schrieb 11.12.23, 04:47
Und in Kurzfassung zur Kapitalerhöhung. Ganz frisch im November initiiert: 5,5 Mio. USD zu 0,6 USD / Aktie eingesammelt. Ordentliche Verwässerung, kein Wunder, dass der Kurs auf diesem Stand erstmal zementiert ist.
Zudem gibt es noch einen Haufen Optionen mit Ausübungspreis 0,85 USD. Da dürfte mit Blick nach oben kurstechnisch rein theoretisch dann erstmal ein gewisser Deckel liegen.
Zielumsatz 2023 von 12 bis 14 Mio. USD bestätigt.
Hier noch die Quelle zu den Kapitalmaßnahmen: https://ontrakhealth.com/investors/press-releases/?qmodStoryID=7313131263294016
"On November 14, 2023, the Company announced the closing of its previously announced public offering of:
4,592,068 shares of its common stock and 9,184,136 warrants to purchase up to 9,184,136 shares of its common stock at a combined public offering price of $0.60 per share of common stock and accompanying warrants, and
5,907,932 pre-funded warrants to purchase up to 5,907,932 shares of its common stock and 11,815,864 warrants to purchase up to 11,815,864 shares of its common stock at a combined public offering price of $0.5999 per pre-funded warrant and accompanying warrants, which represents the per share public offering price for the common stock and accompanying warrants less the $0.0001 per share exercise price for each pre-funded warrant.
The Company estimates net proceeds of approximately $5.5 million from the public offering described above.
In addition, concurrent with the public offering described above, the Company announced the closing of its previously announced concurrent private placement (the “Private Placement”) of $11.0 million worth of unregistered pre-funded warrants to purchase shares of the Company's common stock and unregistered warrants to purchase shares of the Company's common stock to Acuitas. The Company issued 18,333,333 pre-funded warrants to purchase up to 18,333,333 shares of its common stock and 36,666,666 warrants to purchase up to 36,666,666 shares of its common stock at a purchase price of $0.5999 per pre-funded warrant and accompanying warrants, which represents the per share public offering price for the common stock and accompanying warrants less the $0.0001 per share exercise price for each pre-funded warrant. The warrants accompanying the pre-funded warrants have an exercise price of $0.85 per share. The exercisability of such warrants are subject to stockholder approval and, if such approval is obtained, will expire on the fifth anniversary of the date of such approval. The consideration for the Private Placement Securities purchased by Acuitas consisted of (a) the $6.0 million of escrowed funds then held in the escrow account, and (b) a reduction of the aggregate amounts outstanding under the Keep Well Notes (after giving effect to the Notes Conversion) to $2.0 million (the “Surviving Note”). Prior to the closing of the public offering and private placement, Acuitas converted approximately $16.3 million of outstanding senior secured convertible notes, leaving $2.0 million of Surviving Note."
mitdiskutieren » 
USA
